Status of programmed death-ligand 1 expression in sarcomas

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Sarcomas present diagnostic challenges due to rarity and complexity.
• Programmed death-1 (PD-1) and PD-L1 inhibitors show anti-tumor effects in solid tumors.
• PD-L1 expression is linked to treatment response in various cancers.

Purpose of the Study:

• To investigate PD-L1 protein expression across diverse bone and soft tissue sarcoma subtypes.
• To evaluate the association between PD-L1 expression and clinicopathological features in sarcomas.
• To determine the impact of PD-L1 expression on patient survival outcomes.

Main Methods:

• Western blot, flow cytometry, and immunocytochemistry on 16 sarcoma cell lines.
• Immunohistochemistry on 230 patient-derived tumor tissues using three PD-L1 antibody clones.
• Correlation analysis of PD-L1 expression with survival and clinicopathological data.

Main Results:

• PD-L1 protein was highly expressed in pleomorphic rhabdomyosarcoma, fibrosarcoma, and dedifferentiated liposarcoma (DDLPS) cell lines.
• Immunohistochemistry revealed varying PD-L1 immunoreactivity across subtypes and antibody clones.
• In DDLPS, high PD-L1 expression (≥1%) was associated with significantly worse recurrence-free and overall survival.

Conclusions:

• Sarcoma PD-L1 expression is dependent on histologic subtype and antibody clone used.
• Findings provide crucial data for selecting patients for PD-1/PD-L1 inhibitor therapy in sarcoma.
• Further research can refine PD-L1 as a predictive biomarker for sarcoma immunotherapy.